Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: A retrospective, multicenter study (JAMP-neo study).

Yasuhiro Nakamura,Yukiko Kiniwa,Hiroshi Kato,Osamu Yamasaki,Takeo Maekawa,Shigeto Matsushita,Tatsuya Takenouchi,Takashi Inozume,Yasuo Nakai,Satoshi Fukushima,Shintaro Saito,Atsushi Otsuka,Noriki Fujimoto,Taiki Isei,Natsuki Baba,Taisuke Matsuya,Ryo Tanaka,Takahide Kaneko,Masazumi Onishi,Shusuke Yoshikawa

Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: A retrospective, multicenter study (JAMP-neo study).

2021

9542Background: Anti-PD-1 antibody monotherapy (PD1) has been commonly used for patients with advanced acral melanoma (AM). However, recent studies have demonstrated the limited clinical efficacy o...

Keywords:

Internal medicine
Combination therapy
first line
Medicine
acral melanoma
Oncology
anti pd 1
multicenter study
Antibody
Immunotherapy
anti ctla 4

Correction
Source
Cite
Save

References

Citations